Study Summary
This trial is testing if MRI can be used to screen for cancer in people with LFS and other cancer predisposition syndromes.
Eligible Conditions
- Li-Fraumeni Syndrome
Treatment Effectiveness
Phase-Based Effectiveness
N/A
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: 4 years
3 years
Detection of prevalent and incident cancers on WB-MRI in pediatric and adult patients with Li Fraumeni and other inherited cancer predisposition syndromes.
Malignant Neoplasms
4 years
Radionuclide Imaging
Return of pediatric and adult patients with other cancer predisposition syndromes year-after-year for 4 annual scans.
Trial Safety
Phase-Based Safety
Awards & Highlights
No Placebo Group
All patients enrolled in this trial will receive the new treatment.
Trial Design
1 Treatment Group
Whole Body MRI
1 of 1
Experimental Treatment
150 Total Participants · 1 Treatment Group
Primary Treatment: Whole Body MRI · No Placebo Group · N/A
Whole Body MRI
Device
Experimental Group · 1 Intervention: Whole Body MRI · Intervention Types: DeviceTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Whole Body MRI
2007
N/A
~40
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4 years
Who is running the clinical trial?
Dana-Farber Cancer InstituteLead Sponsor
1,029 Previous Clinical Trials
755,685 Total Patients Enrolled
1 Trials studying Li-Fraumeni Syndrome
1,500 Patients Enrolled for Li-Fraumeni Syndrome
Allison O'Neill, MDPrincipal Investigator - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
2 Previous Clinical Trials
18 Total Patients Enrolled
Eligibility Criteria
Age Any Age · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:You have a genetic or hereditary condition that increases your risk for certain types of cancer. This includes Li Fraumeni Syndrome, Hereditary Retinoblastoma, Hereditary Paraganglioma/Pheochromocytoma Syndrome, Multiple Endocrine Neoplasia, Opsoclonus-Myoclonus Syndrome, Familial Neuroblastoma, Rapid-Onset Obesity with Hypothalamic dysfunction, Hypoventilation and Autonomic Dysregulation (ROHHAD syndrome), Congenital Central Hypoventilation Syndrome (CCHS), Von Hippel-Lindau Syndrome, or other rare cancer predisposition syndromes.
Participants must be adults and not children.
You have a rare genetic condition that increases your risk of developing cancer, such as Li Fraumeni Syndrome or other inherited cancer predisposition syndromes.
You must be 18 years of age or older.